Data Analytics Company Definitive Healthcare Acquires PatientFinder
Definitive Healthcare, a Framingham, Mass.-based data analytics and business intelligence company, has announced the acquisition of PatientFinder, a software analytics firm that helps life science companies and healthcare providers find patient clusters who would most benefit from their products and services.
The acquisition, according to Definitive Healthcare officials, supports the company’s vision to entrench contextual data and insights within a business’s end-to-end commercialization effort. PatientFinder technology allows clients to build customized cohorts of patients by analyzing their diagnosis and treatment history and align that intelligence with the physicians and facilities who provide care to those patient populations, they added.
The terms have the deal have not yet been made public.
Definitive’s clients, which include leading pharmaceutical companies, medical device firms, and over 2,500 healthcare providers, healthcare IT, healthcare staffing and consulting firms – utilize the Definitive platform to solve pressing revenue generating objectives. Clients analyze referral patterns, patient leakage trends, total and average charges, patient outcomes, and population health trends to drive a complete end-to-end commercialization effort.
This is the second acquisition for Definitive Healthcare over the past year, following its acquisition of HIMSS Analytics’ data services division in January 2019.
In an interview with Healthcare Purchasing News, Jason Krantz, founder and CEO of Definitive Healthcare, noted that the impact of the deal will be significant for the company’s clients, enabling them “to quickly analyze claims data and find very specific patient cohorts so that they’re able to find patients with certain combinations of procedures, diagnoses, and drug histories. And, in a world of personalized medicine – where the subsegments of patients are becoming smaller and smaller and more specific – this is an incredibly powerful tool for our medical device, biotech, and pharmaceutical clients.”
